A patent victory and pipeline advances that could lead to billions in additional sales helped catapult AbbVie Inc. (NYSE: ABBV) shares 18% higher in September, according to S&P Global Market Intelligence.On September 7, the U.S. Patent Office refused competitor Coherus's request for an inter partes review of AbbVie's U.S. Patent 9,085,619. The decision added strength to claims by AbbVie's management that it can keep Humira copy-cats out of the market in the U.S.